obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Dorothy Anderson, Administrative Officer, Department of Social Security. John Elwyn Anderson. For services to the community, particularly Lifesaving, in South Wales. Royan Stuart Anderson, Constable, Operational Support Unit, British Transport Police. For services to Public Transport. Timothy John Anderson, Sergeant, Derbyshire Constabulary. For services to the Police. Edmund Robert Askey. For services to Tourism in Blackpool, Lancashire. Charles Keith Atkinson. For services to Young People in Nottinghamshire and to Rowing. Elizabeth Atkinson, Member, Northumberland County Council. For services to Local Government. Marjone Oxnard Atkinson. For services to the community on the Pennywell Estate, Sunderland, Tyne and Wear. Peggy Baerlein. For services to the Lister Hospital, Hertfordshire. Beryl Bailey, Support Grade Band 1, Home Office. Peter Edwin Bailey, lately Senior Doorkeeper, House of Lords. Albert John Baker. For services to War Pensions Committees in London. Elsie Evelyn Baker. For services to the Girls' Brigade on Guernsey. Kenneth Walter Ball, lately Honorary Secretary, British Transport Pensioners' Federation. For services to the Railway Industry. Jack Bonner Barlow. For services to Local Councils in the former South Glamorgan and to the community in Sully. Andrew Brown Barr. For services to the Royal Agricultural Benevolent Institution and to the Essex Agricultural Society. Dennis Gordon Bartholomew. For services to the community in Whiston, South Yorkshire. Haydn Sydney Bateman, Auxiliary Coastguard-in-charge, Her Majesty's Coastguard, St Govans, Dyfed.
==== Party name ==== The SPGB had been using the short form of its name, the Socialist Party, for publicity purposes as far back as 1910. In 1988, the party passed a resolution at its annual conference indicating when to use the full-form and short-form names: the full-form name was to be retained as the official name for use on legal documents and publication credits and the short form was to be used for most other purposes, including election ballots and propaganda. This is analogous to how the Conservative and Unionist Party publicises itself as the Conservative Party. The resolution was made partly to codify an existing practice and partly to avoid what some members considered the nationalistic connotation of Great Britain.
April 9: Decree setting the structure, staffing, status, and pay for laboratory personnel (under the Ministry of Public Health): women may be assistants but may not hold leadership positions, nor the roles of head technician or "lab boy." October 30: Decree on child protection. October 30: Decree amending Articles 376 and following of the Civil Code; modifies the "right of parental discipline" — for both father and mother — and the terms and duration of placing a child under care. 1936
The programme is also expected to create over 4 million jobs in the next 4 years (2.5 million direct jobs and 1.5 million indirect jobs). Some economists have criticised the plan, citing Brazil's poor track record of investment quality and worries regarding fiscal responsibility. Of the energy investments, 343 billion will be made through Petrobras, a state-owned corporation notable for its involvement in a corruption scandal during Lula's previous presidency.
Sources: en.wikipedia.org
All of astatine's isotopes are short-lived; the most stable is astatine-210, with a half-life of 8.1 hours. There are 41 known isotopes of astatine, with mass numbers of 188 and 190–229. Theoretical modeling suggests that about 37 more isotopes could exist. No stable or long-lived astatine isotope has been observed, nor is one expected to exist. Astatine's alpha decay energies follow the same trend as for other heavy elements. Lighter astatine isotopes have quite high energies of alpha decay, which become lower as the nuclei become heavier. Astatine-211 has a significantly higher energy than the previous isotope, because it has a nucleus with 126 neutrons, and 126 is a magic number corresponding to a filled neutron shell. Despite having a similar half-life to the previous isotope (8.1 hours for astatine-210 and 7.2 hours for astatine-211), the alpha decay probability is much higher for the latter: 41.81% against only 0.18%. The two following isotopes release even more energy, with astatine-213 releasing the most energy. For this reason, it is the shortest-lived astatine isotope. Even though heavier astatine isotopes release less energy, no long-lived astatine isotope exists, because of the increasing role of beta decay (electron emission). This decay mode is especially important for astatine; as early as 1950 it was postulated that all isotopes of the element undergo beta decay, though nuclear mass measurements indicate that 215At is in fact beta-stable, as it has the lowest mass of all isobars with A = 215.
=== Bioengineering === The subfield of bioengineering concentrates on creating novel metabolic and regulatory pathways, and is currently the one that likely draws the attention of most researchers and funding. It is primarily motivated by the desire to establish biotechnology as a legitimate engineering discipline. When referring to this area of synthetic biology, the word "bioengineering" should not be confused with "traditional genetic engineering", which involves introducing a single transgene into the intended organism. Bioengineers adapted synthetic biology to provide a substantially more integrated perspective on how to alter organisms or metabolic systems. A typical example of single-gene genetic engineering is the insertion of the human insulin gene into bacteria to create transgenic proteins. The creation of whole new signalling pathways, containing numerous genes and regulatory components (such as an oscillator circuit to initiate the periodic production of green fluorescent protein (GFP) in mammalian cells), is known as bioengineering as part of synthetic biology. By utilising simplified and abstracted metabolic and regulatory modules as well as other standardized parts that can be combined to create new pathways or creatures, bioengineering aims to create innovative biological systems. In addition to creating opportunities for novel applications, this strategy is anticipated to make bioengineering more predictable and controllable than traditional biotechnology.
They suggest the toxicity is due to three constituents that work in combination to produce encephalopathy, Pleurocybelline a heat stable and high molecular weight glycoprotein, Pleurocybella porrigens lectin a purified lectin, and Pleurocybellaziridine an amino acid derivative. Experimental studies in rodents showed that the Pleurocybelline and Pleurocybella porrignes lectin form a complex exhibiting non-specific proteolytic activity that disrupts the blood-brain barrier. Injection of this combination into mice resulted in degradation of protein substrates and the disappearance of the marker GLUT1 which indicates disruption of the blood-brain barrier. This activity is proposed to arise from the functional interaction of the two proteins, where their combination gains proteolytic properties not present in either protein alone. This leads to broad degradation of extracellular and membrane associated proteins required for blood-brain barrier disruption. Although neither protein alone is directly neurotoxic, this disruption is proposed to enable Pleurocybellaziridine to enter brain cells. Pleurocybellaziridine was found after the comparison of related amino acid derivatives which led researchers to infer the existence of a precursor. Once the blood-brain barrier is compromised Pleurocybellaziridine was able to access neural tissue, where it is thought to exert cytotoxic effects, particularly on oligodendrocytes.
The United States of America stayed neutral, but some Americans were eager to participate. Early in the war Lord Roberts cabled Major Frederick Russell Burnham, a veteran of both Matabele wars but then prospecting in the Klondike, to serve on his personal staff as Chief of Scouts. Burnham went on to receive the highest awards of any American who served in the war. American mercenaries participated on both sides. Portugal had considerable dealings with the South African Republic through Portuguese Mozambique. The war broke out while Portugal was engaged in its own pacification campaigns in Africa and after the 1890 British Ultimatum Portuguese public opinion was highly favourable to the Boers, but the Portuguese government chose not to hostilize the United Kingdom. Instead it took the opportunity to mend bilateral relations and reaffirm the Anglo-Portuguese alliance through the signing of the Second Treaty of Windsor, by which Britain recognized Portuguese claims in Africa and reaffirmed its pledge to help defend Portugal as well as its overseas empire against all enemies "future and present", in exchange for Portugal not declaring neutrality and providing aid against the Boers, namely by blocking the passage of weapons and ammunitions through its territory and allowing Britain the use of its port facilities. In 1900, 700 Boers crossed into Mozambique to seek refuge, but this group soon grew to 1400-2500. 700-900 were transported to Caldas da Rainha in Portugal, where they were kept until the end of the war.
Lung over-pressure injury in ambient pressure divers using underwater breathing apparatus is usually caused by breath-holding on ascent. The compressed gas in the lungs expands as the ambient pressure decreases causing the lungs to over-expand and rupture unless the diver allows the gas to escape by maintaining an open airway, as in normal breathing. The lungs do not sense pain when over-expanded giving the diver little warning to prevent the injury. This does not affect breath-hold divers as they bring a lungful of air with them from the surface, which merely re-expands safely to near its original volume on ascent. The problem only arises if a breath of ambient pressure gas is taken at depth, which may then expand on ascent to more than the lung volume. Pulmonary barotrauma may also be caused by explosive decompression of a pressurised aircraft, as occurred on 1 February 2003 to the crew in the Space Shuttle Columbia disaster.
Sources: en.wikipedia.org
The Scoville scale is a measure of the hotness of a chili pepper. It is the degree of dilution in sugar water of a specific chili pepper extract when a panel of 5 tasters can no longer detect its "heat". Pure capsaicin (the chemical responsible for the "heat") has 16 million Scoville heat units.
The most common gastrointestinal complications of anorexia nervosa are delayed stomach emptying and constipation, but also include elevated liver function tests, diarrhea, acute pancreatitis, gastroesophageal reflux disease (GERD), difficulty swallowing, and, rarely, superior mesenteric artery syndrome. Acid exposure from GERD and self-induced vomiting can cause dental problems, such as tooth enamel erosion and gum disease. Delayed stomach emptying, or gastroparesis, often develops following food restriction and weight loss; the most common symptom is bloating with gas and abdominal distension, and often occurs after eating. Other symptoms of gastroparesis include early satiety, fullness, nausea, and vomiting. The symptoms may inhibit efforts at eating and recovery, but can be managed by limiting high-fiber foods, using liquid nutritional supplements, or using metoclopramide to increase emptying of food from the stomach. Gastroparesis generally resolves when weight is regained.
==== Eliminated in primary ==== Hector Cabildo, entrepreneur Raul Castaneda, retiree Marisela Chavez, retiree Deliris Montanez Berrios, retired medical worker and Democratic candidate for this district in 2022 Ruben Rios, teacher
Esophageal varices are swollen twisted branches of the azygous vein in the lower third of the esophagus. These blood vessels anastomose (join up) with those of the portal vein when portal hypertension develops. These blood vessels are engorged more than normal, and in the worst cases may partially obstruct the esophagus. These blood vessels develop as part of a collateral circulation that occurs to drain blood from the abdomen as a result of portal hypertension, usually as a result of liver diseases such as cirrhosis. This collateral circulation occurs because the lower part of the esophagus drains into the left gastric vein, which is a branch of the portal vein. Because of the extensive venous plexus that exists between this vein and other veins, if portal hypertension occurs, the direction of blood drainage in this vein may reverse, with blood draining from the portal venous system, through the plexus. Veins in the plexus may engorge and lead to varices. Esophageal varices often do not have symptoms until they rupture. A ruptured varix is considered a medical emergency because varices can bleed a lot. A bleeding varix may cause a person to vomit blood, or suffer shock. To deal with a ruptured varix, a band may be placed around the bleeding blood vessel, or a small amount of a clotting agent may be injected near the bleed. A surgeon may also try to use a small inflatable balloon to apply pressure to stop the wound. IV fluids and blood products may be given in order to prevent hypovolemia from excess blood loss.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.